18:54 , Mar 15, 2018 |  BC Innovations  |  Product R&D

Engineered to kill

Nkarta Inc. is betting that boosting NK cells’ intrinsic ability to discriminate between cancer and healthy cells will increase their efficacy as anti-cancer agents and lower their risk of toxicity compared with the more common...
22:01 , Apr 7, 2017 |  BioCentury  |  Finance

Combo quest

By leading Viracta Therapeutics Inc. ’s series B round and forging a partnership for its lead HDAC inhibitor last week, NantKwest Inc. (NASDAQ:NK) took another step toward bolstering its natural killer cell therapy arsenal. Wicklow...
04:37 , Jan 27, 2017 |  BC Week In Review  |  Clinical News

Allogeneic aNK cells: Ph I QUILT-3.018 data

Data from 7 patients with relapsed or refractory AML in the open-label, U.S. Phase I QUILT-3.018 trial showed that 1×10 9 and 3×10 9 IV aNK cells/m 2 led to no dose-limiting toxicities (DLTs) or...
04:27 , Jan 27, 2017 |  BC Week In Review  |  Clinical News

Allogeneic aNK cells: Preliminary Ph II QUILT-3.009 data

Preliminary data from 3 patients with unresectable stage IIIB or IV MCC in the open-label, U.S. Phase II QUILT-3.009 trial showed that 2x10 9 IV aNK cells/m 2 for 2 consecutive days every 2 weeks...
07:00 , Jul 28, 2016 |  BC Innovations  |  Tools & Techniques

Innate harmony

On the heels of cancer immunotherapy's clinical success, NK cells - a long-known but underappreciated component of the innate immune system - are emerging as the hottest new tool to fight cancer, with the potential...
00:57 , Sep 12, 2015 |  BC Extra  |  Financial News

NantCell raises $100M

NantCell Inc. (Culver City, Calif.) raised $100 million in an equity financing from a single, undisclosed investor, according to an SEC filing. NantCell, which did not respond to inquiries, is one of several subsidiaries of...
07:00 , Aug 3, 2015 |  BioCentury  |  Finance

NK-ocking out cancer

Patrick Soon-Shiong is building what he hopes will be a suite of companies under the NantWorks LLC umbrella that together will help revolutionize cancer treatment. The latest is cancer immunotherapy company NantKwest Inc. (NASDAQ:NK), which...
07:00 , Jun 8, 2015 |  BC Week In Review  |  Company News

Sorrento gene/cell therapy, cancer news

Sorrento established TNK Therapeutics Inc., a wholly owned subsidiary to develop chimeric antigen receptor tumor-attacking Neukoplasts (CAR-TNKs) and other cellular and immunotherapies for solid tumors and hematological malignancies. CAR-TNKs incorporate Neukoplast (NK-92) cell lines from...
02:25 , Jun 4, 2015 |  BC Extra  |  Financial News

Soon-Shiong's NantCell raises $75M

NantCell Inc. raised $75 million in an equity financing from a single investor, according to an SEC filing. NantCell, which did not respond to inquiries, is one of several subsidiaries of Patrick Soon-Shiong's NantWorks LLC...
01:13 , May 16, 2015 |  BC Extra  |  Company News

Sorrento rises on NantWorks deal

Sorrento Therapeutics Inc. (NASDAQ:SRNE) gained $1.51 (13%) to $13.01 on news that its Igdrasol Inc. subsidiary will be acquired by Patrick Soon-Shiong's NantWorks LLC (Los Angeles, Calif.) for $90 million up front. The acquisition will...